1. Clinical & Scientific Overview
Rosuvastatin Calcium (TIP-MED-000017, Reference Code [3.17]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a HMG-CoA Reductase Inhibitor (Hydrophilic, High-Potency Statin).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Lasix (Sanofi), Frusenex (Geno)
Oral Film-Coated Tablets: 5 mg, 10 mg, 20 mg, 40 mg
3. Mechanism of Action & Pharmacodynamics
HMG-CoA Reductase Inhibitor (Hydrophilic, High-Potency Statin) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via HMG-CoA Reductase Inhibitor (Hydrophilic, High-Potency Statin) for Primary hypercholesterolaemia and mixed dyslipidaemia; primary and secondary prevention of cardiovascular events (ASCVD, post-PCI, stroke); slowing progression of atherosclerosis..
4. Therapeutic Indications & Evidence-Supported Uses
- Primary hypercholesterolaemia and mixed dyslipidaemia
- primary and secondary prevention of cardiovascular events (ASCVD, post-PCI, stroke)
- slowing progression of atherosclerosis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 5–20 mg once daily (Start at 5 mg OD in Asian/Indian patients due to 2-fold higher systemic exposure via SLCO1B1/ABCG2 polymorphism). Max 40 mg OD (restricted to severe hypercholesterolaemia under specialist supervision; avoid 40 mg in Asian patients or CrCl <60 mL/min).
Administration & Meal Timing: With or without food. | Any time of day (longest statin half-life ~19 hours); commonly administered at night after dinner.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Mild-to-moderate CKD (CrCl 30–60 mL/min): Start 5 mg OD, avoid 40 mg dose. Severe CKD (CrCl <30 mL/min not on dialysis): Start 5 mg OD; MAX 10 mg/day (contraindicated at 20–40 mg). Hepatic: Contraindicated in active liver disease or Child-Pugh B/C cirrhosis (markedly increased exposure).
Renal: Mild-to-moderate CKD (CrCl 30–60 mL/min): Start 5 mg OD, avoid 40 mg dose. Severe CKD (CrCl <30 mL/min not on dialysis): Start 5 mg OD; MAX 10 mg/day (contraindicated at 20–40 mg). Hepatic: Contraindicated in active liver disease or Child-Pugh B/C cirrhosis (markedly increased exposure).
Renal: Mild-to-moderate CKD (CrCl 30–60 mL/min): Start 5 mg OD, avoid 40 mg dose. Severe CKD (CrCl <30 mL/min not on dialysis): Start 5 mg OD; MAX 10 mg/day (contraindicated at 20–40 mg). Hepatic: Contraindicated in active liver disease or Child-Pugh B/C cirrhosis (markedly increased exposure).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in active liver disease, pregnancy, lactation; 40 mg strength is contraindicated in Asian patients with predisposing myopathy risk factors, moderate-to-severe renal impairment (CrCl <60 mL/min), or fibrate co-therapy.
Key Clinical Precautions: Renal: Mild-to-moderate CKD (CrCl 30–60 mL/min): Start 5 mg OD, avoid 40 mg dose. Severe CKD (CrCl <30 mL/min not on dialysis): Start 5 mg OD; MAX 10 mg/day (contraindicated at 20–40 mg). Hepatic: Contraindicated in active liver disease or Child-Pugh B/C cirrhosis (markedly increased exposure).
8. Adverse Effects Profile
- Myalgia, headache, asthenia, mild GI discomfort, mild benign dipstick proteinuria (tubular origin, especially at 40 mg), slight increase in HbA1c.
- Rhabdomyolysis with acute renal failure, severe myopathy, hepatic transaminase elevation >3x ULN, rare interstitial lung disease.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- OATP1B1/BCRP transporter inhibitors: Cyclosporine (contraindicated or max 5 mg OD), Gemfibrozil (avoid; max 10 mg OD if unavoidable), Darolutamide/Regorafenib/Velpatasvir/Sofosbuvir (markedly increase rosuvastatin AUC)
- Warfarin (may increase INR; check INR within 5–7 days)
- Antacids containing Al/Mg hydroxide decrease absorption by 50% (give antacid 2 hours AFTER rosuvastatin)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: If taking liquid or chewable antacids for acidity, take them at least 2 hours after rosuvastatin so absorption is not blocked. Never stop the tablet once lipid reports normalise. Report diffuse muscle pain or weakness promptly.
- Meal & Clock Timing Instruction: With or without food. (Any time of day (longest statin half-life ~19 hours); commonly administered at night after dinner.)
- Missed Dose Protocol: Take as soon as remembered unless within 12 hours of the next dose; never double the dose.
- Geriatric Dispensing Pearl: Because Indian patients exhibit ~2x higher plasma AUC via SLCO1B1/ABCG2 transporter polymorphism and age-related renal decline, 10 mg–20 mg rosuvastatin achieves potent LDL reduction (>45–55%) in elderly CGHS patients without needing the 40 mg dose.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 5 mg, 10 mg, 20 mg, 40 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.17] (p. 29)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.19] Clopidogrel Bisulfate — Thienopyridine P2Y12 ADP-Receptor Antagonist (Prodrug Antiplatele
- [3.20] Cilostazol — Phosphodiesterase-3 (PDE-3) Inhibitor; Antiplatelet & Direct Arte
- [3.21] Digoxin — Cardiac Glycoside (Na+/K+-ATPase Pump Inhibitor); Positive Inotro
- [3.22] Warfarin Sodium — Vitamin K Epoxide Reductase Complex 1 (VKORC1) Inhibitor (Oral Co
